17,084 Bristol Myers Squibb Company $BMY Shares Sold by North Dakota State Investment Board

North Dakota State Investment Board cut its position in Bristol Myers Squibb Company (NYSE:BMY) by 21.5% during the third quarter, HoldingsChannel reports. The firm owned 62,548 shares of the biopharmaceutical company’s stock after selling 17,084 shares during the quarter. North Dakota State Investment Board’s holdings in Bristol Myers Squibb were worth $3,903,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of BMY. Altura Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 1.2% during the 3rd quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock worth $856,000 after purchasing an additional 161 shares during the last quarter. Capital City Trust Co. FL increased its holdings in Bristol Myers Squibb by 0.7% in the third quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock valued at $1,455,000 after buying an additional 167 shares during the last quarter. Eagle Bay Advisors LLC increased its holdings in Bristol Myers Squibb by 2.6% in the third quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock valued at $408,000 after buying an additional 168 shares during the last quarter. Boltwood Capital Management increased its holdings in Bristol Myers Squibb by 2.5% in the third quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company’s stock valued at $443,000 after buying an additional 170 shares during the last quarter. Finally, Sandy Cove Advisors LLC raised its stake in Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 176 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Trading Down 1.7%

Shares of Bristol Myers Squibb stock opened at $60.51 on Thursday. The company has a fifty day simple moving average of $62.98 and a 200-day simple moving average of $59.88. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock has a market cap of $123.59 billion, a price-to-earnings ratio of 13.33, a PEG ratio of 0.31 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same period last year, the firm posted $1.46 EPS. The company’s revenue was up 5.7% on a year-over-year basis. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.51 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is 55.51%.

Analysts Set New Price Targets

BMY has been the subject of a number of recent analyst reports. Citigroup reaffirmed a “neutral” rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Bank of America lowered their price objective on Bristol Myers Squibb from $71.00 to $66.00 in a research report on Friday, October 9th. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. The Goldman Sachs Group raised Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 16th. Finally, Piper Sandler decreased their target price on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $65.50.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: A Bristol Myers Squibb cancer drug reportedly doubled progression-free survival in a study and also showed encouraging results in other solid tumors. The data could strengthen the company’s growth portfolio and help offset concerns about future product declines. Bristol Myers Squibb Cancer Drug Trial Article
• Positive Sentiment: One valuation analysis argues that BMY still trades below its estimated fair value and highlights the company’s cash-generation potential. That view may attract value-oriented investors following the stock’s substantial one-year advance. Bristol Myers Squibb Fair Value Analysis
• Neutral Sentiment: Bristol Myers Squibb is scheduled to report third-quarter results before the market opens Thursday. Pre-earnings coverage is focused on revenue, earnings, full-year guidance and performance from key growth products, making the report the next major catalyst for BMY. Bristol Myers Squibb Q3 2026 Earnings Preview
• Neutral Sentiment: Analyst opinions remain divided. A consolidated fair-value estimate fell from $66.71 to $65.25, while individual targets range from the $50s to the $80s, reflecting differing expectations for pipeline data, potential corporate actions and future cash flows. Bristol Myers Squibb Fair Value and Analyst Views
• Negative Sentiment: Piper Sandler cut its price target for BMY, adding pressure to the shares ahead of earnings. The target reduction suggests more cautious expectations for near-term operating performance or the company’s pipeline. Piper Sandler Price Target Cut
• Negative Sentiment: Zacks Research made small cuts to its fiscal 2027 and 2028 EPS estimates and maintains a “Hold” rating. The lower forecasts reinforce concerns that earnings may decline beyond the current year, when analysts expect approximately $6.51 per share. Bristol Myers Squibb Analyst Estimates

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.